UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating
On May 28, UBS lowered the firm's price target on Westlake Corporation (NYSE:WLK) from $118 to $101, while keeping a Buy rating on the stock. The adjustment reflects the near-term challenges for the company's Performance and Essential Materials (PEM) Segment.
A closeup of a Petrochemical product being inspected for quality assurance.
The company reported its fiscal first quarter results for 2025 on May 2. The company reported net sales of $2.85 billion down from $2.98 billion a year ago. The PEM segment faced headwinds from a strong run-up in feedstock and increased energy prices which led the net sales down from $1.91 billion in Q1 2024 to $1.85 billion in the recent quarter. The higher cost also led the EBITDA of the PEM segment to be $180 million lower than the previous year.
The firm still sees Westlake Corporation's (NYSE:WLK) commodity products as favorably priced in the market. However, UBS anticipates continued challenges for the near-term at least thereby leading to a reduced price target.
Westlake Corporation (NYSE:WLK) is an international manufacturer of materials and products. It provides building blocks for major industries including housing and construction. Packaging, healthcare, automotive, and consumer goods. It operates through two main segments: Performance and Essential Materials (PEM) and Housing and Infrastructure Products.
While we acknowledge the potential of WLK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WLK and that has 100x upside potential, check out our report about the .
READ NEXT: and .
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, designed to be a potentially pivotal study, with ALTO-207 in patients with TRD by mid-2026 and report topline data in 2027 – – Cash guidance unchanged; current cash is expected to fund planned operations into 2028, through at least five planned clinical study readouts – – Company to host conference call and webcast today, June 3, at 8 a.m. ET – MOUNTAIN VIEW, Calif., June 03, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally defined as a failure on two or more antidepressants. The most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 is designed to enable rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. ALTO-207 is being developed to address the significant unmet need for patients with TRD. "The expansion of our pipeline aligns with Alto's mission to drive innovation in psychiatry through novel therapeutic solutions," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "With proprietary insights on dopamine biomarkers in depression that enable targeted neuropsychiatric drug development, we are uniquely positioned to advance ALTO-207, a differentiated, late-stage product candidate with robust clinical effects to date, which are supported with historical pramipexole data. The fixed-dose combination of pramipexole and ondansetron offers a novel treatment strategy designed to optimize for a rapid treatment effect with faster titration, and balance safety and tolerability at high doses. We believe the convenience of a single prescribable agent will also improve compliance and support clinician and patient adoption. Leveraging our targeted biomarker approach to stratify for TRD patients most likely to respond to treatment, we look forward to building on the positive Phase 2a results and initiating a Phase 2b trial, with a potentially pivotal design, by mid-2026." Dr. Etkin continued, "The strategic transaction with Chase Therapeutics allows us to add a major late-stage clinical readout to our pipeline without changing our current cash runway guidance into 2028. Broadly, we believe this opportunity underscores the robust value of our precision platform and bolsters our prospects for long-term growth through driving innovation in psychiatry." Thomas Chase, M.D., President and Chief Executive Officer of Chase Therapeutics Corporation, added, "Supported by the robust clinical effects in our completed Phase 2a study, we believe CTC-501, has the potential to address the critical need for more effective, mechanistically distinct interventions for patients with TRD. Given Alto's expertise in dopamine-related products in depression, we believe they are an ideal partner to maximize the therapeutic potential of our portfolio in depression and Parkinson's disease. We look forward to seeing Alto continue this exciting momentum as they work toward realizing our shared vision for patients." Michael Browning, DPhil, MRCP, MRCPsych, Professor of Computational Psychiatry, University of Oxford, commented, "I am highly encouraged by the recently completed PAX-D study of pramipexole, which suggests a greater and more durable effect than other available TRD treatments. However, pramipexole is not well tolerated and when it is, it requires slow titration due to dose-limiting AEs. The clinical utility of pramipexole would be greatly enhanced by improving the dose-limiting tolerability profile. Emerging data suggests that ALTO-207 could address these challenges, and be well positioned to treat this large and underserved patient population." Alto acquired CTC-501 (now ALTO-207), in development for depression, and CTC-413 (now ALTO-208), in development for Parkinson's disease. Both product candidates are novel patent-protected dopamine agonists. About the Completed Phase 2a Trial for CTC-501 Chase Therapeutics completed a randomized, placebo-controlled Phase 2a clinical trial evaluating CTC-501 in 32 patients with depression. The study consisted of two periods, a dose titration period in which patients were dosed with increasing dose levels of CTC-501 or placebo at increments of 1 mg/day (or matching placebo) until the maximum allowed dose (or first intolerable dose) was reached. Patients were then maintained for an eight-week treatment period at either the maximum allowed dose or their maximum tolerated dose (1 mg/day lower than their first intolerable dose in the titration period). The primary endpoint in the study was defined as overall tolerability and achievement of higher dose levels of pramipexole when combined with ondansetron. Clinical efficacy was evaluated as a secondary exploratory endpoint in the study. The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day with 67% of patients achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study. The clinical efficacy measures were evaluated as secondary endpoints and across measures CTC-501 demonstrated large, clinically meaningful, effects. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scalef, or MADRS (LSM Δ vs. placebo at Week 8 = -8.2, p=0.025, Cohen's d=1.1). CTC-501 also demonstrated a significantly greater improvement compared to placebo on the Clinician Global Impression Scale of Severity, or CGI-S (LSM Δ vs. placebo at Week 8 = -0.76, p=0.04, Cohen's d=1.0). About the Completed Phase 2a Trial for CTC-413 ALTO-208 is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD). Chase Therapeutics completed a blinded Phase 2a clinical trial evaluating CTC-413 (pramipexole co-administered with aprepitant) in 13 patients with PD. The study consisted of two periods. Patients in the treatment group were initially titrated to the maximum allowed dose of standard pramipexole extended release (4.5 mg/day). Patients were then switched to CTC-413 until the maximum allowed dose of 9mg/day (or first intolerable dose) was reached. Following three months of maintenance, patients returned to their pre-study regimen for final assessment. The mean tolerated dose of CTC-413 significantly exceeded pramipexole (p<0.001). Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues. About the Transaction Under the terms of the asset purchase agreement, Alto paid Chase Therapeutics an upfront payment of $1.75 million, and Chase Therapeutics will be eligible for up to an aggregate of $71.5 million in future milestone payments related to prespecified development and commercial milestones. $41 million of the potential future milestone payments are tied to commercial success of the product candidates. Alto's financial guidance remains unchanged. The Company expects its current cash balance to support planned operations into 2028, now through five clinical trial readouts across its pipeline programs. Conference Call and Webcast at 8:00 a.m. ET Today Alto Neuroscience will host a conference call today at 8:00 a.m. ET to discuss the acquisition of a novel dopamine agonist combination product candidate. The call will feature Michael Browning, Professor of Computational Psychiatry at the University of Oxford, and Alan Schatzberg, M.D., Professor of Psychiatry and Behavioral Sciences at Stanford University. To listen to the live webcast, please visit Alto's investor relations website. Participants may register for the call here. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. For more information, visit or follow Alto on X. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "expects," "plans," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform ("Platform"); Alto's expectations with regard to the design and results of its clinical trials; the reproducibility of positive clinical data seen in prior trials of CTC-501/ALTO-207; Alto's clinical and regulatory development plans for ALTO-207; the competitive landscape and potential market opportunities for ALTO-207; and Alto's anticipated cash runway. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled "Risk Factors" in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Availability of Information on Alto's Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website. View source version on Contacts Investor and Media Contact: Mari Purpurainvestors@ media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Davidson Instruments, Inc. sues Parker-Hannifin Corporation, alleging antitrust violations, theft of trade secrets, and copyright infringement and other acts due to fraudulent patent filings based on Davidson trade secrets
THE WOODLANDS, Texas, June 03, 2025--(BUSINESS WIRE)--Davidson Instruments, a world leader in the development of fiber optic pressure measurement systems for use in harsh industrial applications, alleges that Parker-Hannifin Corporation (NYSE: PH) is responsible for the filing of a fraudulent patent application in 2024, other fraudulent patent filings, and other acts of theft and misappropriation of Davidson's trade secrets. Davidson's trade secrets can eliminate greenhouse gas emissions and also maximize fuel efficiency in jet engines and other industrial combustion turbine engines when used with advanced combustion control systems. Davidson alleges that Parker misappropriated Davidson's proven trade secret technology after Parker failed to develop a similar fiber optic pressure sensing system through an initiative that it began in 2013. Davidson further alleges that Parker has been attempting to use fraudulent patent filings to control the market for innovations of Davidson's fiber optic sensing technology for use in jet engines. Davidson believes it is entitled to damages of at least $900,000,000 and certain injunctive relief. The case is: Davidson Instruments, Inc. v. Parker-Hannifin Corporation, 2:25-cv-00520, filed on May 12, 2025, in the U.S. District Court for the Eastern District of Texas, in Marshall, Texas. A redacted public copy of the lawsuit is available on Davidson's website: View source version on Contacts Media Contact:Healey, Danielle, Spencer Fane LLPdhealey@ 713-552-1234 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Allegion Acquires Novas, Adding Another Premium Brand to High-Quality Australian Door Hardware Portfolio
DUBLIN, June 03, 2025--(BUSINESS WIRE)--Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, through one of its subsidiaries, has acquired Nova Hardware Pty Ltd (Novas), an architectural door hardware business based in Victoria, Australia. Founded in 1996, Novas is a trusted brand among developers, architects and builders. Known for its high-quality security portfolio, Novas designs and sells mechanical and electronic locks, door closers and seals, hinges, pulls and levers as well as master keying solutions, primarily in Australian multifamily and commercial markets. Novas is strategically aligned to Allegion's presence in the region, and this acquisition offers both companies expanded opportunities for growth. Novas will report into the Allegion International segment, led by Allegion Senior Vice President Tim Eckersley. "This acquisition underscores Allegion's commitment to investing in our core and delivering added value for our channel partners, customers and shareholders, alike," Eckersley said. "Together, Novas and Allegion will continue building a legacy of strong Australian brands that create exceptional end user experiences while making the world safer and more accessible." Todd Foster, owner of Novas, will join Allegion in an advisory capacity to facilitate a smooth transition and support accelerated growth for the combined organizations. "This is an exciting new chapter for the Novas door hardware business," Foster said. "Allegion shares our values of innovation, customer focus and operational excellence. With Allegion's resources and global reach, we have an incredible opportunity to scale our business and provide even more meaningful differentiation in our markets." Terms of the transaction were not disclosed. This transaction excludes the kitchen and bathroom businesses of Novas, which will be retained by the owner and formed as a separate entity. About Allegion At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We're pioneering safety with our strong legacy of leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. Allegion had $3.8 billion in revenue in 2024. For more, visit View source version on Contacts Media Contact: Whitney Moorman – Director, Global Analyst Contact: Jobi Coyle – Director, Investor Josh Pokrzywinski – Vice President, Investor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
